Edoxaban improves atrial fibrillation and thromboembolism through regulation of the Wnt‑β‑induced PI3K/ATK‑activated protein C system

Shan,Xuefeng; Liu,Zhiqiang; Wulasihan,Muhuyati; Ma,Songfeng

doi:10.3892/etm.2019.7379

Edoxaban improves atrial fibrillation and thromboembolism through regulation of the Wnt‑β‑induced PI3K/ATK‑activated protein C system

Authors:
- Xuefeng Shan
- Zhiqiang Liu
- Muhuyati Wulasihan
- Songfeng Ma
View Affiliations

Affiliations: Department of Pediatric Surgery, The First Affiliated Hospital, Xinjiang Medical University, Urumchi, Xinjiang 830054, P.R. China, Comprehensive Heart Internal Medicine, Heart Center of The First Affiliated Hospital, Xinjiang Medical University, Urumchi, Xinjiang 830054, P.R. China
Published online on: March 13, 2019 https://doi.org/10.3892/etm.2019.7379
Pages: 3509-3517
Copyright: © Shan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thromboembolism is a commonly observed condition in geriatrics that is caused by vascular endothelial injury, platelet activation, physiological coagulation processes, reduction of anticoagulant activity, decreased fibrinolytic activity and abnormal flow in the heart chamber, artery or vein. The protein C anticoagulant system serves a crucial role in anticoagulant therapy for the treatment of thromboembolism. Previous findings have suggested that edoxaban is an efficient oral anticoagulant in the acute treatment of venous thromboembolism. In the present study, the efficacy of edoxaban on thromboembolism induced by atrial fibrillation was investigated in a mouse model. Inflammatory factors interleukin (IL)‑1, ‑4, ‑8 and tumor necrosis factor (TNF)‑α were analyzed in the sera of mice with fibrillation induced by thromboembolism. Expression and activity of thymic stromal lymphopoietin (TSLP) and activated protein C resistance were investigated in platelets and vascular endothelial cells (VECs). TSLP‑induced platelet viability, Wnt‑β phosphorylation and integrin expression were analyzed in platelets. Furthermore, Wnt‑β expression and the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT) signaling pathway in VECs were analyzed. Results demonstrated that the expression levels of IL‑1, ‑4, ‑8 and TNF‑α were significantly downregulated in the sera of mice with fibrillation and thromboembolism following treatment with edoxaban (P<0.01). Furthermore, the expression levels of prostacyclin (PGI2), prostaglandin (PG)E2, PGD2 and PGF2α were significantly increased in the sera of experimental mice that received edoxaban therapy (P<0.01). Results also indicated that edoxaban significantly stimulated the protein expression of TSLP and activated Wnt‑β phosphorylation and integrin expression in platelets (P<0.01). In addition, edoxaban therapy significantly upregulated the expression levels of PI3K and AKT, and subsequently increased the activity of protein C and S in VECs (P<0.01). Notably, edoxaban treatment improved atrial fibrillation and thromboembolism, as determined by pathological analysis. In conclusion, these results suggested that edoxaban elicited beneficial effects for mice with atrial fibrillation induced by thromboembolism through the regulation of the Wnt‑β‑induced PI3K/ATK‑activated protein C system.

View Figures

View References

1	Lim MS and Enjeti AK: Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: Report of 5 cases and literature review. Crit Rev Oncol Hematol. 105:92–99. 2016. View Article : Google Scholar : PubMed/NCBI
2	Nagler M, Kremer Hovinga JA, Alberio L, Peter-Salonen K, von Tengg-Kobligk H, Lottaz D, Neerman-Arbez M and Lämmle B: Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review. Thromb Haemost. 116:722–732. 2016. View Article : Google Scholar : PubMed/NCBI
3	Shlebak A: Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: A case series and a review. J Clin Pathol. 69:337–343. 2016. View Article : Google Scholar : PubMed/NCBI
4	Samoš M, Bolek T, Ivanková J, Stančiaková L, Kovář F, Galajda P, Kubisz P, Staško J and Mokáň M: Heparin induced thrombocytopenia presenting with deep venous thrombosis and pulmonary embolism successfully treated with rivaroxaban: Clinical case report and review of current experiences. J Cardiovasc Pharmacol. 68:391–394. 2016. View Article : Google Scholar : PubMed/NCBI
5	McKeage K and Keating GM: Parnaparin: A review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 68:105–122. 2008. View Article : Google Scholar : PubMed/NCBI
6	Pellegrini VD Jr: Prophylaxis against venous thromboembolism after total hip and knee arthroplasty: A critical analysis review. JBJS Rev. 3:01874474-201509000-00005. 2015. View Article : Google Scholar : PubMed/NCBI
7	Devlin R, Bonanno L and Badeaux J: The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: A systematic review. JBI Database System Rev Implement Rep. 14:116–138. 2016. View Article : Google Scholar : PubMed/NCBI
8	Barco S, Atema JJ, Coppens M, Serlie MJ and Middeldorp S: Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: A systematic review and critical appraisal. Blood. 15:369–377. 2017.
9	Piazza G, Mani V, Goldhaber SZ, Grosso MA, Mercuri M, Lanz HJ, Schussler S, Hsu C, Chinigo A, Ritchie B, et al: Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Vasc Med. 21:361–368. 2016. View Article : Google Scholar : PubMed/NCBI
10	Maehama T, Okura H, Imai K, Saito K, Yamada R, Koyama T, Hayashida A, Neishi Y, Kawamoto T and Yoshida K: Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation. J Cardiol. 56:118–124. 2010. View Article : Google Scholar : PubMed/NCBI
11	Nishimura S: Pathogenesis of chronic inflammation revealed by in vivo imaging: Thrombus formation and platelet function. Rinsho Ketsueki. 51:620–624. 2010.(In Japanese). PubMed/NCBI
12	Mo XR, Luo XJ, Li CP, Pan XF and Zhou LL: Effect of mannitol injection by intravenous catheter on ear vein endothelial cell apoptosis and venous thrombus in rabbits. Eur Rev Med Pharmacol Sci. 19:491–497. 2015.PubMed/NCBI
13	Shirai Y, Noguchi T, Kita S, Nakamura A, Tanimoto H, Ishigaki N, Aoyama K and Yoshida T: A study of usefulness for portal vein thrombus with edoxaban. Nihon Shokakibyo Gakkai Zasshi. 113:439–440. 2016.(In Japanese). PubMed/NCBI
14	Fei D, Meng X, Zhao M, Kang K, Tan G, Pan S, Luo Y, Liu W, Nan C, Jiang H, et al: Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis. Transl Res. 159:99–109. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lozano M, Escolar G, Schwarz HP, Hernández R, Bozzo J and Ordinas A: Activated protein C inhibits thrombus formation in a system with flowing blood. Br J Haematol. 95:179–183. 1996. View Article : Google Scholar : PubMed/NCBI
16	Hadas K, Randriamboavonjy V, Elgheznawy A, Mann A and Fleming I: Methylglyoxal induces platelet hyperaggregation and reduces thrombus stability by activating PKC and inhibiting PI3K/Akt pathway. PLoS One. 8:e744012013. View Article : Google Scholar : PubMed/NCBI
17	Yi W, Li Q, Shen J, Ren L, Liu X, Wang Q, He S, Wu Q, Hu H, Mao X and Zhu L: Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161. PLoS One. 9:e1023942014. View Article : Google Scholar : PubMed/NCBI
18	Srivastava AK, Kalita J, Haris M, Gupta RK and Misra UK: Radiological and histological changes following cerebral venous sinus thrombosis in a rat model. Neurosci Res. 65:343–346. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-based quantitative assay for screening of kidney stone disease. Biol Proced Online. 11:145–160. 2009. View Article : Google Scholar : PubMed/NCBI
20	Naganuma Y, Ichii O, Otsuka S, Hashimoto Y and Kon Y: Analysis of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells associated with cardiac myogenesis in mouse embryo. J Vet Med Sci. 75:283–290. 2013. View Article : Google Scholar : PubMed/NCBI
21	González-Manchón C, Larrucea S, Pastor AL, Butta N, Arias-Salgado EG, Ayuso MS and Parrilla R: Compound heterozygosity of the GPIbalpha gene associated with Bernard-Soulier syndrome. Thromb Haemost. 86:1385–1391. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hawbaker S: Venous thromboembolism in the cancer population: Pathology, risk, and prevention. J Adv Pract Oncol. 3:23–33. 2012.PubMed/NCBI
23	Vitale C, D'Amato M, Calabro P, Stanziola AA, Mormile M and Molino A: Venous thromboembolism and lung cancer: A review. Multidiscip Respir Med. 10:282015. View Article : Google Scholar : PubMed/NCBI
24	Ungprasert P, Tanratana P and Srivali N: Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 136:1013–1017. 2015. View Article : Google Scholar : PubMed/NCBI
25	Fernandez MM, Hogue S, Preblick R and Kwong WJ: Review of the cost of venous thromboembolism. Clinicoecon Outcomes Res. 7:451–462. 2015. View Article : Google Scholar : PubMed/NCBI
26	Santin BJ, Lohr JM, Panke TW, Neville PM, Felinski MM, Kuhn BA, Recht MH and Muck PE: Venous duplex and pathologic differences in thrombus characteristics between de novo deep vein thrombi and endovenous heat-induced thrombi. J Vasc Surg Venous Lymphat Disord. 3:184–189. 2015. View Article : Google Scholar : PubMed/NCBI
27	Corral J, Huntington JA, González-Conejero R, Mushunje A, Navarro M, Marco P, Vicente V and Carrell RW: Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost. 2:931–939. 2004. View Article : Google Scholar : PubMed/NCBI
28	Vayá A, Gómez I, Mira Y, Ferrando F and Corella D: Homocysteine levels in patients with deep vein thrombosis lacking thrombophilic defects. Thromb Haemost. 99:1132–1134. 2008. View Article : Google Scholar : PubMed/NCBI
29	Dittmeier M, Wassmuth K, Schuhmann MK, Kraft P, Kleinschnitz C and Fluri F: Dabigatran etexilate reduces thrombin-induced inflammation and thrombus formation in experimental ischemic stroke. Curr Neurovasc Res. 13:199–206. 2016. View Article : Google Scholar : PubMed/NCBI
30	Pulimamidi VK, Murugesan V, Rajappa M, Satheesh S and Harichandrakumar KT: Increased levels of markers of oxidative stress and inflammation in patients with rheumatic mitral stenosis predispose to left atrial thrombus formation. J Clin Diagn Res. 7:2445–2448. 2013.PubMed/NCBI
31	Empana JP, Boulanger CM, Tafflet M, Renard JM, Leroyer AS, Varenne O, Prugger C, Silvain J, Tedgui A, Cariou A, et al: Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. Eur Heart J Acute Cardiovasc Care. 4:28–36. 2015. View Article : Google Scholar : PubMed/NCBI
32	Sadowski M, Zabczyk M and Undas A: Coronary thrombus composition: Links with inflammation, platelet and endothelial markers. Atherosclerosis. 237:555–561. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li N, Guo W, Shi J, Xue J, Hu H, Xie D, Wu M and Cheng S: Expression of the chemokine receptor CXCR4 in human hepatocellular carcinoma and its role in portal vein tumor thrombus. J Exp Clin Cancer Res. 29:1562010. View Article : Google Scholar : PubMed/NCBI
34	Yadava K, Sichelstiel A, Luescher IF, Nicod LP, Harris NL and Marsland BJ: TSLP promotes influenza-specific CD8+ T-cell responses by augmenting local inflammatory dendritic cell function. Mucosal Immunol. 6:83–92. 2013. View Article : Google Scholar : PubMed/NCBI
35	Janda J, Plattet P, Torsteinsdottir S, Jonsdottir S, Zurbriggen A and Marti E: Generation of equine TSLP-specific antibodies and their use for detection of TSLP produced by equine keratinocytes and leukocytes. Vet Immunol Immunopathol. 147:180–186. 2012. View Article : Google Scholar : PubMed/NCBI
36	Tate CM, Blosser W, Wyss L, Evans G, Xue Q, Pan Y and Stancato L: LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J Biol Chem. 288:6743–6753. 2013. View Article : Google Scholar : PubMed/NCBI
37	Diaz JA, Wrobleski SK, Pechota AR, Hawley AE, Roelofs KJ, Doornbos NK, Gabriel JE, Reynolds G, Lester P, Londy F, et al: P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor. J Vasc Surg Venous Lymphat Disord. 2:1142014. View Article : Google Scholar : PubMed/NCBI
38	Rossaint J, Vestweber D and Zarbock A: GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost. 11:335–344. 2013. View Article : Google Scholar : PubMed/NCBI
39	Guidetti GF, Canobbio I and Torti M: PI3K/Akt in platelet integrin signaling and implications in thrombosis. Adv Biol Regul. 59:36–52. 2015. View Article : Google Scholar : PubMed/NCBI
40	Su W, Chen Y, Wang C, Ding X, Rwibasira G and Kong Y: Human cathelicidin LL-37 inhibits platelet aggregation and thrombosis via Src/PI3K/Akt signaling. Biochem Biophys Res Commun. 473:283–289. 2016. View Article : Google Scholar : PubMed/NCBI
41	McFadyen J and Peter K: Forget about thrombosis: Platelets and Alzheimer's disease, yet another sticky situation. Sci Signal. 9:fs92016. View Article : Google Scholar : PubMed/NCBI